TGFB1 and type 2 diabetes mellitus: Importantly, we found that anti-inflammatory and immune suppressive cytokine TGF-β1 was markedly increased in the plasma of T2D subjects post-treatment at four weeks relative to the baseline levels (Figure 2A).